CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Telmisartan more effective than Carvedilol in preventing recurrent atrial fibrillation episodes in patients with hypertension and atrial fibrillation


Atrial remodelling, leading to atrial fibrillation, is mediated by the renin-angiotensin-aldosterone system.

Mild hypertensive outpatients ( systolic/diastolic blood pressure 140-159/90-99 mmHg ) in sinus rhythm who had experienced greater than or equal to 1 electrocardiogram (ECG)-documented atrial fibrillation episode in the previous six months received randomly Telmisartan ( Micardis ) 80 mg/day or Carvedilol ( Coreg, Dilatrend ) 25 mg/day.

Blood pressure and 24-hour ECG were monitored monthly for one year; patients were asked to report symptomatic atrial fibrillation episodes and to undergo an ECG as early as possible.

One hundred and thirty-two patients completed the study ( Telmisartan, n=70; Carvedilol, n=62 ).

Significantly fewer atrial fibrillation episodes were reported with Telmisartan versus Carvedilol ( 14.3% vs. 37.1%; p less than 0.003 ).

Left atrial diameter, assessed by echocardiography, was similar with Telmisartan and Carvedilol ( 3.4±2.3 cm vs. 3.6±2.4 cm ).

At study end, both regimes significantly reduced mean left ventricular mass index, but the reduction obtained with Telmisartan was significantly greater than with Carvedilol ( 117.8±10.7 vs 124.7±14.5; p less than 0.0001 ).

Mean blood pressure values were not significantly different between the groups ( Telmisartan 154/97 to 123/75 mmHg; p less than 0.001; Carvedilol 153/94 to 125/78 mmHg; p less than 0.001 ).

In conclusion, Telmisartan was significantly more effective than Carvedilol in preventing recurrent atrial fibrillation episodes in hypertensive patients with atrial fibrillation, despite a similar lowering of blood pressure. ( Xagena )

Galzerano D et al, J Renin Angiotensin Aldosterone Syst 2012;13:496-503

XagenaMedicine_2012



Indietro